- Home
- RF vs INSM Comparison
RF vs INSM Comparison
Compare RF & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RF
- INSM
- Stock Information
- Founded
- RF 1970
- INSM 1988
- Country
- RF United States
- INSM United States
- Employees
- RF N/A
- INSM N/A
- Industry
- RF Major Banks
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- RF Finance
- INSM Health Care
- Exchange
- RF Nasdaq
- INSM Nasdaq
- Market Cap
- RF 19.2B
- INSM 17.3B
- IPO Year
- RF N/A
- INSM 2000
- Fundamental
- Price
- RF $22.20
- INSM $102.68
- Analyst Decision
- RF Buy
- INSM Strong Buy
- Analyst Count
- RF 20
- INSM 17
- Target Price
- RF $25.25
- INSM $106.80
- AVG Volume (30 Days)
- RF 8.7M
- INSM 4.1M
- Earning Date
- RF 07-18-2025
- INSM 08-07-2025
- Dividend Yield
- RF 4.52%
- INSM N/A
- EPS Growth
- RF 11.56
- INSM N/A
- EPS
- RF 2.07
- INSM N/A
- Revenue
- RF $6,661,000,000.00
- INSM $381,030,000.00
- Revenue This Year
- RF $16.19
- INSM $28.03
- Revenue Next Year
- RF $4.24
- INSM $120.54
- P/E Ratio
- RF $10.69
- INSM N/A
- Revenue Growth
- RF N/A
- INSM 20.77
- 52 Week Low
- RF $17.74
- INSM $60.40
- 52 Week High
- RF $27.96
- INSM $102.70
- Technical
- Relative Strength Index (RSI)
- RF 57.19
- INSM 78.76
- Support Level
- RF $21.40
- INSM $98.46
- Resistance Level
- RF $21.86
- INSM $102.00
- Average True Range (ATR)
- RF 0.41
- INSM 3.50
- MACD
- RF -0.01
- INSM 2.61
- Stochastic Oscillator
- RF 78.49
- INSM 99.61
About RF Regions Financial Corporation
Regions Financial is a regional bank based in Alabama, with branches primarily in the Southeastern and Midwestern United States. Regions primarily provides traditional commercial and retail banking and also offers mortgage services, asset management, wealth management, securities brokerage, and trust services.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.